Lefty inhibitors belong to a distinct class of chemical compounds known for their pivotal role in regulating embryonic development and cell differentiation. These inhibitors are closely associated with the transforming growth factor-beta (TGF-β) superfamily of signaling molecules. To understand Lefty inhibitors, it's essential to appreciate their role within the intricate process of embryogenesis. During early development, Lefty inhibitors play a fundamental role in establishing the body plan of an organism. They are known for their function in maintaining symmetry and axis formation, a critical step in the early stages of embryonic development. Lefty inhibitors act as antagonists to certain signaling pathways within the TGF-β superfamily, exerting their influence by interfering with the signaling molecules involved. Specifically, they counteract the activity of Nodal, an important TGF-β member, which plays a key role in specifying the left-right axis in vertebrates. By doing so, Lefty inhibitors help ensure that the developing embryo forms with appropriate bilateral symmetry, preventing developmental abnormalities and ensuring the proper organization of vital organs.
Lefty inhibitors can be broadly classified into two isoforms: Lefty-1 and Lefty-2. Both isoforms exhibit similar mechanisms of action, working as negative regulators by binding to Nodal and inhibiting its signaling. This function is crucial for maintaining the balance of the Nodal pathway, preventing excessive or inappropriate signaling that could lead to developmental defects. Lefty inhibitors are a prime example of the delicate checks and balances that govern embryonic development. Their presence ensures the precise orchestration of signaling pathways, guaranteeing that an organism's body plan and symmetry are established correctly during its early stages of development. Understanding the mechanisms of Lefty inhibitors is not only essential for developmental biology but also holds potential implications for various fields of science and medicine, shedding light on the intricacies of cell signaling and differentiation.
VEJA TAMBÉM
Items 1 to 10 of 15 total
Mostrar:
Nome do Produto | CAS # | Numero de Catalogo | Quantidade | Preco | Uso e aplicacao | NOTAS |
---|---|---|---|---|---|---|
BIBF1120 | 656247-17-5 | sc-364433 sc-364433A | 5 mg 10 mg | $180.00 $315.00 | 2 | |
O nintedanib é um inibidor da tirosina quinase que tem como alvo múltiplos receptores, incluindo o VEGFR, o FGFR e o PDGFR, inibindo as vias da angiogénese e da fibrose. | ||||||
Imatinib mesylate | 220127-57-1 | sc-202180 sc-202180A | 25 mg 100 mg | $44.00 $109.00 | 61 | |
O imatinib inibe a tirosina quinase BCR-ABL, impedindo a sinalização aberrante na leucemia mieloide crónica (LMC) e nos tumores do estroma gastrointestinal (GIST). | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $73.00 $238.00 $717.00 $2522.00 $21420.00 | 53 | |
Este composto inibe amplamente a transcrição e pode reduzir a expressão de numerosos genes, incluindo o LEFTY. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
O sorafenib tem como alvo as cinases RAF e VEGFR, interrompendo as vias MAPK e VEGF, que desempenham um papel no crescimento e disseminação das células. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
O erlotinib inibe a tirosina quinase EGFR, bloqueando as vias de sinalização a jusante envolvidas na promoção do crescimento e da divisão celular | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Um inibidor da tradução de proteínas que pode reduzir a síntese de proteínas LEFTY. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
O sunitinib inibe o VEGFR, o PDGFR e outras cinases, interferindo na angiogénese e na proliferação das células tumorais, sendo utilizado principalmente no carcinoma das células renais. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
O gefitinib é um inibidor da tirosina quinase do EGFR, que interrompe o crescimento e a divisão das células através da interrupção das vias de sinalização impulsionadas pelo EGFR. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
O dasatinib tem como alvo o BCR-ABL e outras cinases, suprimindo a proliferação de células leucémicas, sendo utilizado principalmente na leucemia mieloide crónica (LMC). | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $35.00 $115.00 $515.00 | 26 | |
Dada a ligação cruzada entre a sinalização Wnt e TGF-β, inibidores como o XAV-939 ou o ICG-001 podem modular indiretamente a expressão ou a atividade do LEFTY. |